Intelligence · Patent portfolio
Xenon Pharmaceuticals Patents
Full USPTO pharma patent portfolio for Xenon Pharmaceuticals — grant dates, expiration, and drug cross-links.
- Patents
- 106
- Expiring ≤24m
- 5
Quick answer
Xenon Pharmaceuticals has 106 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 5 expire within 24 months — use filters for patent-cliff planning.
-
US 7456180
Piperazine derivatives and their use as therapeutic agents
granted -
US 7390813
Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
granted -
US 7335658
Pyridazine derivatives and their use as therapeutic agents
granted -
US 7297523
Human elongase genes and uses thereof
granted -
US 7294480
High throughput screening assays using fatty acid synthetic enzymes
granted -
US 7256028
Methods for screening compounds that modulate lipid metabolism
granted -
US 7166584
Cholesterol transport gene
granted -
US 6987001
Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents
expired -
US 6759208
High throughput screening assays using fatty acid synthetic enzymes
expired -
US 6617122
Process for identifying modulators of ABC1 activity
expired
Frequently asked questions
How many patents does Xenon Pharmaceuticals have?
106 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Xenon Pharmaceuticals patents expire?
5 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory